The October 15 short interest data has been compared with the September 30 figures, and the trend in biotech leaders had changed from directional to short sellers becoming stock-specific in their focus. Amgen Inc. (NASDAQ: AMGN) saw its …
Traders faced front and center as continued turmoil in Italy weighed on major stock indexes as details of France’s new …
AMGN Earnings in Focus The company reported earnings of $2.30 ... Gilead's shares dropped 4% in extending market trading on account of the Solvadi sales miss. Though the stock might trade lower for some more days, it nonetheless …
We expect shares to trade off on the elevated expenses though the stock market was arguably prepared for it with ... and 3.8% dividend yield. Amgen (AMGN): Reiterate outperform rating. Remain buyers after a solid fourth quarter beat and …
Amgen Inc. (NASDAQ: AMGN) is one the top blue-chip stocks in the biotech world ... Deutsche Bank has a $195 price objective for the stock. The Thomson/First Call consensus price target is $176.32. The stock closed Tuesday at $154.24.
Analysts are optimistic about the quarter. Credit Suisse's Alethia Young reiterated a Neutral rating Amgen, but she has a $194 price target, comfortably above the …
On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal – making it the fifth-largest biotech deal in history …
traders are definitely monitoring Bristol-Myers Squibb’s price action to see if this move attracts further buying into the stock. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that develops, …
Drug stocks are soaring Wednesday, after Democratic presidential candidate Hillary Clinton, who had outlined plans to to curb drug price increases was defeated by Republican Donald Trump. Morgan Stanley analysts summed up the sigh of …